CTNM Hedge Fund Ownership (Q2 2026)

Q: Is it too late to buy Contineum Therapeutics Inc (CTNM) following the 2026 Q3 hedge fund 13F filings?

As of today, CTNM has moved +0.0% since the 2026 Q3 13F filing date (November 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (September 30, 2026), CTNM gained -28.3% vs +11.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Contineum Therapeutics Inc (CTNM)

101 + Investors. Track Smart Money conviction in CTNM. See who's accumulating, reducing, or initiating positions.

Smart Money Signals — CTNM

Based on 102 hedge funds · latest filing: 2026 Q2 · updated quarterly

📈

Buying streak — 3 quarters in a row

last 6Q

For 3 consecutive quarters, more hedge funds added CTNM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

🏔️

At the ownership peak (100% of max)

100% of all-time peak

102 hedge funds hold CTNM right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.

🚀

Fast accumulation — +44% more funds vs a year ago

fund count last 6Q

+31 new funds entered over the past year (+44% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.

🟢

More buyers than sellers — 63% buying

63 buying37 selling

Last quarter: 63 funds were net buyers (31 opened a brand new position + 32 added to an existing one). Only 37 were sellers (19 trimmed + 18 sold completely). A clear majority buying is a strong confirmation signal.

📈

More new buyers each quarter (+8 vs last Q)

new funds entering per quarter

Funds opening a new CTNM position: 14 → 31 → 23 → 31. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.

🔄

Mostly new holders — 46% entered in last year

■ 23% conviction (2yr+) ■ 31% medium ■ 46% new

Only 23 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

💰

Price up while funds trimmed (+25% value, -1% shares)

Value

+25%

Last quarter: total value of institutional CTNM holdings rose +25% even though funds reduced share count by 1%. The stock price increased enough to offset the selling. Institutions are quietly trimming into price strength — watch for rotation.

📈

Growing discovery — still being found

27 → 14 → 31 → 23 → 31 new funds/Q

New funds entering each quarter: 14 → 31 → 23 → 31. A growing number of institutions are discovering CTNM each quarter. The narrative is still spreading — leaving room for ongoing capital accumulation.

📊

Mixed cohorts — 3% veterans, 50% new entrants

■ 3% veterans ■ 48% 1-2yr ■ 50% new

Of 103 current holders: 3 (3%) held 2+ years, 49 held 1–2 years, 51 (50%) entered in the past year. Balanced distribution — some institutional memory, some recent momentum buyers.

✅

Strong quality — 31% AUM from major funds

31% from top-100 AUM funds

31 of 102 holders rank in the top 100 by AUM, accounting for 31% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

4.9

out of 10

Moderate Exit Risk

Exit risk score 4.9/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Metric	All 13F Filers (2026 Q2)	Prior (2026 Q1)	Change
Funds Holding	101	89	13.48%
13F Shares	31M	31M	-0.57%
Total Value	$500M	$399M	25.26%
New Positions	30	23	+7
Increased Positions	31	28	+3
Closed Positions	18	13	+5
Reduced Positions	19	21	-2
Total Calls	1	1	-
Total Puts	0	0	-
PUT/CALL Ratio	0.0	0.0	Bullish

Metric

All 13F Filers (2026 Q2)

Prior (2026 Q1)

Change

Funds Holding

101

13.48%

13F Shares

31M

-0.57%

Total Value

$500M

$399M

25.26%

New Positions

Increased Positions

Closed Positions

Reduced Positions

-2

Total Calls

Total Puts

PUT/CALL Ratio

0.0

Bullish

Institutional Holders (2026 Q3)

101 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in CTNM. Verified SEC 13F-HR filings.

QUARTER:

2026 Q3 filings are still coming in. Only funds that have filed so far are shown — top holders may not have reported yet. Full 13F data typically settles by ~50 days after quarter-end.

FILTER:All New Added To Reduced No Change | Overweight >5%

Top 25 CTNM holders by conviction (% of portfolio weight) — 2026 Q2 · Source: SEC Form 13F
#	Investor	% of Portfolio	Shares	Mkt Value
1	Red Tree Management, LLC	7.34%	638,158	$8.6M
2	Sectoral Asset Management Inc	5.88%	689,587	$9.3M
3	Johnson & Johnson	3.49%	1,979,173	$26.6M
4	HighVista Strategies LLC	0.77%	217,788	$2.9M
5	Silverarc Capital Management, LLC	0.25%	158,964	$2.1M
6	Persistent Asset Partners Ltd	0.08%	22,852	$307K
7	Strategies Wealth Advisors, LLC	0.06%	50,000	$671K
8	Y-Intercept (Hong Kong) Ltd	0.03%	98,428	$1.3M
9	Profund Advisors LLC	0.01%	37,851	$508K
10	Quantbot Technologies LP	0.01%	26,976	$362K
11	RBF Capital, LLC	0.01%	20,000	$268K
12	China Universal Asset Management Co., Ltd.	0.01%	11,692	$134K
13	Independent Financial Group, LLC	0.01%	27,021	$363K
14	Franklin Templeton Inc	0.00%	1,704,550	$16.7M
15	Alps Advisors Inc	0.00%	43,357	$582K
16	Qube Research & Technologies Ltd	0.00%	167,688	$2.3M
17	Torren Management, LLC	0.00%	254	$3K
18	Fmr LLC	0.00%	2,610,248	$35.0M
19	Ameritas Investment Partners, Inc.	0.00%	2,439	$33K
20	Police & Firemen's Retirement System of New Jersey	0.00%	7,927	$106K
21	Cornerstone Financial Management LLC	0.00%	64	—
22	Vanguard Fiduciary Trust Co	0.00%	202,420	$2.7M
23	Allspring Global Investments Holdings, LLC	0.00%	20,456	$275K
24	Vanguard Capital Management LLC	0.00%	1,362,397	$18.3M
25	Rhumbline Advisers	0.00%	34,449	$462K

Investor	Ownership History	% of Portfolio	Prev %	Rank	Conviction	Avg Buy Price	13F Score™ 3Y / 7Y	Sell Timing	Shares	Mkt Value	Change	Change %	Source	Quarter	Filed

Frequently Asked Questions — Contineum Therapeutics Inc (CTNM)

What does the Smart Money Trend signal show for CTNM?

Buying streak — 3 quarters in a row: For 3 consecutive quarters, more hedge funds added CTNM than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for CTNM?

More buyers than sellers — 63% buying: Last quarter: 63 funds were net buyers (31 opened a brand new position + 32 added to an existing one). Only 37 were sellers (19 trimmed + 18 sold completely). A clear majority buying is a strong confirmation signal.

What is the fund quality score for CTNM holders?

Strong quality — 31% AUM from major funds: 31 of 102 holders rank in the top 100 by AUM, accounting for 31% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held CTNM?

Mostly new holders — 46% entered in last year: Only 23 funds (23%) have held >2 years. The majority of current holders are relatively new to the position. New holders tend to sell faster when prices drop — a shallow conviction base that could amplify any sell-off.

Is it too late to buy Contineum Therapeutics Inc (CTNM) following the 2026 Q3 hedge fund 13F filings?

As of today, CTNM has moved +0.0% since the 2026 Q3 13F filing date (November 14, 2026), compared to +0.0% for the XLV sector ETF — an outperformance of +0.0%. Since the quarter end (September 30, 2026), CTNM has gained -28.3% vs +11.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Market Cap	--
Enterprise Value	--
Trailing P/E	--
Forward P/E	--
PEG Ratio (5yr expected)	--
Price/Sales (ttm)	--
Price/Book (mrq)	--
Enterprise Value/Revenue	--
Enterprise Value/EBITDA	--
Beta (5Y Monthly)	--
Short Ratio (Days to Cover)	--
Short % of Float	--

Profit Margin	--
Return on Assets (ttm)	--
Return on Equity (ttm)	--

Revenue (ttm)	--
Net Income Avi to Common (ttm)	--
Diluted EPS (ttm)	--
Total Cash (mrq)	--
Total Debt/Equity (mrq)	--
Levered Free Cash Flow (ttm)	--

Contineum Therapeutics Inc (CTNM)

Smart Money Signals — CTNM

Buying streak — 3 quarters in a row

At the ownership peak (100% of max)

Fast accumulation — +44% more funds vs a year ago

More buyers than sellers — 63% buying

More new buyers each quarter (+8 vs last Q)

Mostly new holders — 46% entered in last year

Price up while funds trimmed (+25% value, -1% shares)

Growing discovery — still being found

Mixed cohorts — 3% veterans, 50% new entrants

Strong quality — 31% AUM from major funds

Institutional Sentiment Summary — CTNM

Hedge Fund Ownership: CTNM

Market Analysis: CTNM

Analyst Price Targets

Analyst Recommendations

Stock Performance

Company Profile: CTNM

Is It Too Late to Buy Contineum Therapeutics Inc (CTNM) Based on Hedge Fund 13F Filings?

Hedge Fund Positioning: CTNM

Statistics: CTNM

Valuation Measures Data as of: --

Financial Highlights

Institutional Holders (2026 Q3)

Frequently Asked Questions — Contineum Therapeutics Inc (CTNM)

Welcome to 13Foresight!